MGTX trades 120.8% below Wall Street's consensus target of $25.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes MGTX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, MeiraGTx Holdings plc (MGTX) has a Wall Street consensus price target of $25.00, based on estimates from 6 covering analysts. With the stock currently trading at $11.32, this represents a potential upside of +120.8%. The company has a market capitalization of $1.05B.
Analyst price targets range from a low of $24.00 to a high of $26.00, representing a 8% spread in expectations. The median target of $25.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, MGTX trades at a trailing P/E of -8.0x. Analysts expect EPS to grow -8.8% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ADVMAdverum Biotechnologies, Inc. | $96M | $4.36 | — | — | — | — | — |
OCGNOcugen, Inc. | $420M | $1.24 | $5.00 | +303.2% | Buy | — | 6 |
EDITEditas Medicine, Inc. | $263M | $2.69 | $5.00 | +85.9% | Buy | — | 25 |
CRSPCRISPR Therapeutics AG | $5.2B | $54.09 | $71.67 | +32.5% | Buy | — | 38 |
NTLAIntellia Therapeutics, Inc. | $1.8B | $15.67 | $26.13 | +66.8% | Buy | — | 39 |
BEAMBeam Therapeutics Inc. | $3.5B | $34.14 | $48.00 | +40.6% | Buy | — | 27 |
SGMOSangamo Therapeutics, Inc. | $75M | $0.18 | $7.25 | +3927.8% | Hold | — | 14 |
ARWRArrowhead Pharmaceuticals, Inc. | $11.5B | $81.82 | $84.00 | +2.7% | Buy | — | 21 |
IONSIonis Pharmaceuticals, Inc. | $12.2B | $74.12 | $109.44 | +47.7% | Buy | — | 32 |
ALNYAlnylam Pharmaceuticals, Inc. | $37.1B | $278.09 | $454.27 | +63.4% | Buy | 37.1x | 52 |
Quick answers to the most common questions about buying MGTX stock.
The consensus Wall Street price target for MGTX is $25, representing 120.8% upside from the current price of $11.32. With 6 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
MGTX has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $25 implies 120.8% upside from current levels.
MGTX's current price is $11.32 with a consensus target of $25 (120.8% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $26 for MGTX, while the most conservative target is $24. The consensus of $25 represents the median expectation. These targets typically reflect 12-month expectations.
MGTX is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month MGTX stock forecast based on 6 Wall Street analysts shows a consensus price target of $25, with estimates ranging from $24 (bear case) to $26 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on MGTX, with a "Buy" consensus rating and $25 price target (120.8% upside). 6 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
MGTX analyst price targets range from $24 to $26, a 8% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $25 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.